First-in-Class Drug Approved for IgA Nephropathy

Vera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade) (VERA)

Vera Therapeutics faces tough IgAN competition as Trutakna looks late and undifferentiated. A rich valuation adds risk. Read the latest analysis on the VERA stock here.

Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug

Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy

Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.

First-in-Class Drug Approved for IgA Nephropathy

(MedPage Today) -- The FDA granted accelerated approval to atacicept (Trutakna) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Data from ORIGIN 3 supported approval of the once-weekly self-administered...

US FDA approves Vera’s kidney disease drug

July 7 (Reuters) - The U.S. Food and Drug Administration has ​approved Vera Therapeutics' ‌drug to treat patients with a potentially life-threatening kidney disease, the regulator ‌said ​on ⁠Tuesday, sending its ⁠shares up 6.2% in afternoon trading. Th...

FDA approves Vera Therapeutics kidney disease treatment

The drug was approved for the treatment of IgA nephropathy, a chronic autoimmune condition drawing wide interest from biotech companies.